Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
2006 1
2008 1
2009 9
2010 10
2011 20
2012 28
2013 9
2014 11
2015 8
2016 3
2017 7
2018 4
2019 6
2020 7
2021 7
2022 5
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 24856782

117 results

Results by year

Filters applied: . Clear all
Page 1
Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.
Liang XF, Wang HQ, Wang JZ, Fang HH, Wu J, Zhu FC, Li RC, Xia SL, Zhao YL, Li FJ, Yan SH, Yin WD, An K, Feng DJ, Cui XL, Qi FC, Ju CJ, Zhang YH, Guo ZJ, Chen PY, Chen Z, Yan KM, Wang Y. Liang XF, et al. Lancet. 2010 Jan 2;375(9708):56-66. doi: 10.1016/S0140-6736(09)62003-1. Epub 2009 Dec 15. Lancet. 2010. PMID: 20018364 Clinical Trial.
Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial.
Nicholson KG, Abrams KR, Batham S, Clark TW, Hoschler K, Lim WS, Medina MJ, Nguyen-Van-Tam JS, Read RC, Warren FC, Zambon M. Nicholson KG, et al. Lancet Infect Dis. 2011 Feb;11(2):91-101. doi: 10.1016/S1473-3099(10)70296-6. Epub 2010 Dec 16. Lancet Infect Dis. 2011. PMID: 21168369 Clinical Trial.
Randomized, double-blind, multi-center, phase III clinical trial to evaluate the immunogenicity and safety of MG1109 (egg-based pre-pandemic influenza A/H5N1 vaccine) in healthy adults.
Song JY, Choi MJ, Noh JY, Choi WS, Cheong HJ, Wie SH, Lee JS, Woo GJ, Lee SH, Kim WJ. Song JY, et al. Hum Vaccin Immunother. 2017 May 4;13(5):1190-1197. doi: 10.1080/21645515.2016.1263410. Epub 2016 Dec 20. Hum Vaccin Immunother. 2017. PMID: 27996363 Free PMC article. Clinical Trial.
A randomised, partially observer blind, multicentre, head-to-head comparison of a two-dose regimen of Baxter and GlaxoSmithKline H1N1 pandemic vaccines, administered 21 days apart.
Nicholson KG, Abrams KR, Batham S, Clark TW, Hoschler K, Lim WS, Medina M, Nguyen-Van-Tam JS, Read RC, Warren FC, Zambon M. Nicholson KG, et al. Health Technol Assess. 2010 Dec;14(55):193-334. doi: 10.3310/hta14550-04. Health Technol Assess. 2010. PMID: 21208550 Free article. Clinical Trial.
Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico.
López-Macías C, Ferat-Osorio E, Tenorio-Calvo A, Isibasi A, Talavera J, Arteaga-Ruiz O, Arriaga-Pizano L, Hickman SP, Allende M, Lenhard K, Pincus S, Connolly K, Raghunandan R, Smith G, Glenn G. López-Macías C, et al. Vaccine. 2011 Oct 13;29(44):7826-34. doi: 10.1016/j.vaccine.2011.07.099. Epub 2011 Aug 2. Vaccine. 2011. PMID: 21816199 Free PMC article. Clinical Trial.
Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: a Phase 1 dose-escalation study in healthy adults.
Cummings JF, Guerrero ML, Moon JE, Waterman P, Nielsen RK, Jefferson S, Gross FL, Hancock K, Katz JM, Yusibov V; Fraunhofer USA Center for Molecular Biotechnology Study Group. Cummings JF, et al. Vaccine. 2014 Apr 17;32(19):2251-9. doi: 10.1016/j.vaccine.2013.10.017. Epub 2013 Oct 12. Vaccine. 2014. PMID: 24126211 Free PMC article. Clinical Trial.
117 results